Oncology – Urological
Single-arm phase 2b study: MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer.
20 Jun, 2022 | 00:56h | UTCMRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In single-arm phase IIb trial of MRI-guided focused ultrasound therapy in 101 men with primary, group 2‒3 intermediate-risk untreated prostate adenocarcinomas, 88% had no evidence of group ≥2 prostate cancer in the treated area at 2 years: https://t.co/xLpqfFm8Ds #PCSM
— NatureRevClinOncol (@NatRevClinOncol) June 16, 2022
Long-term results of RCT: Radiotherapy to the prostate for men with metastatic prostate cancer.
10 Jun, 2022 | 11:10h | UTC
New study associates intake of dairy milk with greater risk of prostate cancer.
10 Jun, 2022 | 10:50h | UTCOriginal Study: Dairy foods, calcium intakes, and risk of incident prostate cancer in Adventist Health Study–2 – American Journal of Clinical Nutrition (link to abstract – $ for full-text)
RCT: Abiraterone and Olaparib for metastatic castration-resistant prostate cancer.
9 Jun, 2022 | 10:21h | UTCAbiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer – NEJM Evidence
Commentary on Twitter
Combination treatment with abiraterone and olaparib increased progression-free survival regardless of homologous recombination repair gene mutation status in patients with metastatic castration-resistant #ProstateCancer treated in the first-line setting. https://t.co/CAUDF2ZErG pic.twitter.com/YARZa8AUXJ
— NEJM Evidence (@NEJMEvidence) June 3, 2022
Circulating tumor DNA as a biomarker in patients with stage III and IV Wilms tumor.
8 Jun, 2022 | 10:43h | UTCCommentary: Analysis of Circulating Tumor DNA as a Biomarker in Stage III and IV Wilms Tumor – The ASCO Post
Nationwide cohort study: Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer.
3 Jun, 2022 | 11:10h | UTCCommentary: ADT for Prostate Cancer: What’s the Risk on the Heart? – Medscape (free registration required)
Clinical practice guidelines for penile cancer.
2 Jun, 2022 | 10:57h | UTC
Cohort Study: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer.
1 Jun, 2022 | 10:59h | UTCNews Release: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer – Karolinska Institute
Original Study: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA Oncology (link to abstract – $ for full-text)
Authors Interview: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA
Commentary: Large study finds no increased risk for prostate cancer death with 5-ARI use – medwire News
Commentary on Twitter
This large population-based cohort study found that men treated with 5α-reductase inhibitors had no increased risk of dying from #prostatecancer, on the contrary indicating a decreased risk with longer treatment duration. https://t.co/y8HlpthNI9 #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) May 19, 2022
10-yr follow-up of a phase 3 RCT: chemoradiotherapy in muscle-invasive bladder cancer.
30 May, 2022 | 10:52h | UTC
Commentary on Twitter
Chemoradiotherapy in MIBC: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trialhttps://t.co/x8EFIoiqla@Prof_Nick_James @ProfSyedHussain @robert_huddart @NPortaStat
"Long-term findings confirm the benefit of adding 5-FU and MMC to RT for MIBC" pic.twitter.com/bKWSWhwemB
— European Urology (@EUplatinum) May 19, 2022
Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.
26 May, 2022 | 10:42h | UTC
Cohort Study: Risk of venous thromboembolism in men with prostate cancer compared with men in the general population.
25 May, 2022 | 11:01h | UTCNews Release: Men with prostate cancer have a higher risk of serious blood clots – BMJ
Commentary on Twitter
Men with prostate cancer have a 50% higher risk of developing venous thrombosis during the 5 years following their cancer diagnosishttps://t.co/RrYAB5lSrb pic.twitter.com/VGMI7GILgE
— K Pavithran (@drkpavithran) May 24, 2022
Under a http://creativecommons.org/licenses/by-nc/4.0/ license
RCT: The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy.
18 May, 2022 | 10:49h | UTCThe addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial – The Lancet (link to abstract – $ for full-text)
M-A: Comparison of radiofrequency ablation vs. cryoablation For T1 renal tumors.
18 May, 2022 | 10:25h | UTC
Cohort Study: Survival outcomes associated with cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma.
17 May, 2022 | 10:41h | UTC
Commentary on Twitter
In this cohort study, instrumental variable analysis did not find a survival advantage associated with cytoreductive nephrectomy for patients with metastatic clear cell renal cell carcinoma. https://t.co/iljbmtZW4f
— JAMA Network Open (@JAMANetworkOpen) May 16, 2022
RCT: Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs. open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer.
16 May, 2022 | 02:35h | UTCEditorial: Robotic Surgery for Bladder Cancer – JAMA
Commentary on Twitter
In this trial, robot-assisted surgery vs open surgery for radical cystectomy among patients with #bladdercancer resulted in a statistically significantly greater number of days alive and out of the hospital. https://t.co/icPLiKH0Lf
— JAMA (@JAMA_current) May 15, 2022
AUA/ASTRO Guideline: Clinically localized prostate cancer.
13 May, 2022 | 11:10h | UTCHomepage: Clinically Localized Prostate Cancer: AUA/ASTRO Guideline – American Urological Association
Part I: Introduction, Risk Assessment, Staging and Risk-Based Management
Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up
Part III: Principles of Radiation and Future Directions
Related:
Therapies for Clinically Localized Prostate Cancer – Agency for Healthcare Research and Quality
Radical prostatectomy versus deferred treatment for localised prostate cancer – Cochrane Library
Review: Assessment and management of cognitive function in patients with prostate cancer treated with second-generation androgen receptor pathway inhibitors.
10 May, 2022 | 10:32h | UTC
First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment.
6 May, 2022 | 10:27h | UTC
Review: A global approach to improving penile cancer care.
5 May, 2022 | 09:55h | UTCA global approach to improving penile cancer care – Nature Reviews Urology (if the link is paywalled, try this one)
RCT: Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer.
3 May, 2022 | 10:38h | UTC
Commentary on Twitter
? #JCO #ClinicalTrialUpdate: ARCHES trial – ? Enzalutamide + ADT improved OS in men with metastatic horomone-sensitive #ProstateCancer ? https://t.co/FQ1lViCTZz #PCSM @AarmstrongDuke pic.twitter.com/fLs6PdFYlr
— Journal of Clinical Oncology (@JCO_ASCO) April 27, 2022
Guideline: Management of small renal masses.
28 Apr, 2022 | 10:36h | UTCSee also: Summary of Recommendations
Review: Germline testing and genetic counselling in prostate cancer.
28 Apr, 2022 | 08:11h | UTCGermline testing and genetic counselling in prostate cancer – Nature Reviews Urology (if the link is paywalled, try this one at PMC)
M-A: Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavorable prostate cancer.
26 Apr, 2022 | 07:51h | UTC
Consensus Statement: Management of patients with advanced prostate cancer.
25 Apr, 2022 | 00:50h | UTC
Commentary on Twitter
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021https://t.co/GjTGPx8IbN@APCCC_Lugano @Silke_Gillessen @AOmlin @AarmstrongDuke @piet_ost @Prof_IanD @DrSpratticus @charlesryanmd @Tilki_De @declangmurphy pic.twitter.com/FU0Fbjf8WZ
— European Urology (@EUplatinum) April 22, 2022
Phase 2 RCT: Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer.
24 Apr, 2022 | 23:53h | UTC
Commentary on Twitter
In the phase II NEOBLADE trial in 120 pts with locally advanced MIBC, addition of the multitarget RTK TKI nindetanib to neoadjuvant chemotherapy did not significantly improve the pCR rate: 37% versus 32% (OR 1.25, 70% CI 0.84–1.87; P=0.28): https://t.co/m9NXouhOcZ #blcsm
— NatureRevClinOncol (@NatRevClinOncol) April 22, 2022